ArticleJournal of circulating biomarkers
Anti-CENP-A/B reactivity in samples exhibiting the centromere HEp-2 pattern is associated with a lower frequency of interstitial lung disease in limited cutaneous systemic sclerosis patients.
Article in Journal of circulating biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-centromere antibodies are associated with limited cutaneous systemic sclerosis (lcSSc) and a more favorable prognosis. The centromere HEp-2 pattern (AC-3) suggests the presence of antibodies against CENP antigens, mainly CENP-B/A. This study analyzed clinical and demographic associations of anti-centromere antibodies in a cohort of patients exclusively with the lcSSc form of SSc. The frequency of CENP-B and CENP-A reactivity in samples with the AC-3 pattern was also evaluated. Method: Samples from 38 lcSSc patients with AC-3 were evaluated for reactivity to CENP-B/A using line-blot and ELISA. Clinical data from 68 lcSSc patients (20 AC-3 and 48 Non-AC-3) were analyzed. Results: Of the AC-3 samples, 84% and 82% were reactive against CENP-B and CENP-A, respectively, by line-blot, and 92% were positive for CENP-B by ELISA. Concordance for CENP-B reactivity between ELISA and line-blot was 79%. Reactivity to both CENP-B and CENP-A was found in 68% of AC-3 samples, while one sample was positive only for CENP-A. Overall, 97% of AC-3 samples were reactive to CENP-B, and all were reactive to either CENP-B or CENP-A. Clinically, interstitial lung disease (ILD) was less frequent in AC-3 patients compared to Non-AC-3 (10.5% vs. 54.2%; p = 0.001). Other organ involvement frequencies were similar. Conclusion: ILD was less frequent in lcSSc patients with a positive AC-3 pattern as compared to those with a non-AC-3 pattern, which could suggest a less severe prognosis. In addition, anti-CENP-B was the predominant autoantibody in samples yielding the AC-3 pattern, but anti-CENP-A reactivity was also prevalent, and exclusive anti-CENP-A reactivity was also observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.